Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04390763 · ClinicalTrials.gov registry record · Phase 2
Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 164
- Enrollment target
NCT04390763 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 164 participants.
The verdict
NCT04390763, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 164 participants
- Enrollment target
Study Summary
The purpose of this Phase II study is to assess the efficacy and safety of NIS793 with and without spartalizumab in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel in previously untreated mPDAC.
Interventions
- DRUG nab-paclitaxel
- DRUG gemcitabine
- BIOLOGICAL Spartalizumab
- BIOLOGICAL NIS793
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 164 participants |
| Start Date | 2020-10-16 |
| Est. Completion | 2024-05-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04390763
The ClinicalTrials.gov registry entry for NCT04390763 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 164 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which nab-paclitaxel is the first listed.
NCT04390763 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04390763 about?
NCT04390763 is a clinical study titled "Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)". The purpose of this Phase II study is to assess the efficacy and safety of NIS793 with and without spartalizumab in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel in previously untreated mPDAC.
What is the current status of trial NCT04390763?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 164 participants. The study started on 2020-10-16. Estimated completion is 2024-05-02.
What interventions are being tested in trial NCT04390763?
The interventions under investigation include: nab-paclitaxel (DRUG), gemcitabine (DRUG), Spartalizumab (BIOLOGICAL), NIS793 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04390763?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.